DE69828881T2 - Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen - Google Patents

Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen Download PDF

Info

Publication number
DE69828881T2
DE69828881T2 DE69828881T DE69828881T DE69828881T2 DE 69828881 T2 DE69828881 T2 DE 69828881T2 DE 69828881 T DE69828881 T DE 69828881T DE 69828881 T DE69828881 T DE 69828881T DE 69828881 T2 DE69828881 T2 DE 69828881T2
Authority
DE
Germany
Prior art keywords
acetyl
carnitine
acid
use according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69828881T
Other languages
German (de)
English (en)
Other versions
DE69828881D1 (de
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE69828881D1 publication Critical patent/DE69828881D1/de
Publication of DE69828881T2 publication Critical patent/DE69828881T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Percussion Or Vibration Massage (AREA)
DE69828881T 1997-06-18 1998-06-12 Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen Expired - Fee Related DE69828881T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM970365 1997-06-18
IT97RM000365A IT1291930B1 (it) 1997-06-18 1997-06-18 Composizione riequilibratrice delle turbe dell'umore in individui sani
PCT/IT1998/000157 WO1998057629A1 (en) 1997-06-18 1998-06-12 Composition for controlling mood disorders in healthy individuals

Publications (2)

Publication Number Publication Date
DE69828881D1 DE69828881D1 (de) 2005-03-10
DE69828881T2 true DE69828881T2 (de) 2006-01-19

Family

ID=11405131

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828881T Expired - Fee Related DE69828881T2 (de) 1997-06-18 1998-06-12 Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen

Country Status (13)

Country Link
US (1) US6335021B1 (cg-RX-API-DMAC7.html)
EP (1) EP1001760B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002505681A (cg-RX-API-DMAC7.html)
KR (1) KR20010013887A (cg-RX-API-DMAC7.html)
AT (1) ATE288265T1 (cg-RX-API-DMAC7.html)
AU (1) AU7930498A (cg-RX-API-DMAC7.html)
CA (1) CA2294589A1 (cg-RX-API-DMAC7.html)
DE (1) DE69828881T2 (cg-RX-API-DMAC7.html)
DK (1) DK1001760T3 (cg-RX-API-DMAC7.html)
ES (1) ES2236910T3 (cg-RX-API-DMAC7.html)
IT (1) IT1291930B1 (cg-RX-API-DMAC7.html)
PT (1) PT1001760E (cg-RX-API-DMAC7.html)
WO (1) WO1998057629A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806307B1 (fr) * 2000-03-20 2002-11-15 Mane Fils V Preparation parfumee solide sous forme de microbilles et utilisation de ladite preparation
JP4387105B2 (ja) * 2001-03-04 2009-12-16 アイシーユー・メディカル・インコーポレーテッド インフュージョンハブアセンブリおよび流体ライン切断システム
WO2002096411A1 (en) * 2001-05-29 2002-12-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20040071681A1 (en) * 2002-10-10 2004-04-15 Lydia Muller Method and composition for reducing cravings for a craved substance
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
DE602004022301D1 (de) * 2003-05-29 2009-09-10 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
JP2006137746A (ja) * 2004-10-13 2006-06-01 Otsuka Pharmaceut Factory Inc オレキシン誘導組成物
US20070015495A1 (en) * 2005-07-15 2007-01-18 Agilis Systems, Inc. Mobile resource location-based customer contact methods
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8068991B2 (en) * 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US20070124219A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
PT2582368T (pt) 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
MX2022012693A (es) 2020-05-15 2022-11-07 Alfasigma Spa Composicion que comprende metilfolato.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340759A1 (en) * 1988-05-06 1989-11-08 MAGIS FARMACEUTICI S.p.A. Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters
JP3942207B2 (ja) 1995-02-17 2007-07-11 武田薬品工業株式会社 うつ性症状改善剤
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
US6066664A (en) * 1997-06-06 2000-05-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for decreasing the appetite in bulimic, overweight individuals

Also Published As

Publication number Publication date
EP1001760B1 (en) 2005-02-02
ITRM970365A1 (it) 1998-12-18
DK1001760T3 (da) 2005-05-23
JP2002505681A (ja) 2002-02-19
PT1001760E (pt) 2005-04-29
US6335021B1 (en) 2002-01-01
ATE288265T1 (de) 2005-02-15
ES2236910T3 (es) 2005-07-16
IT1291930B1 (it) 1999-01-21
EP1001760A1 (en) 2000-05-24
CA2294589A1 (en) 1998-12-23
KR20010013887A (ko) 2001-02-26
AU7930498A (en) 1999-01-04
WO1998057629A1 (en) 1998-12-23
DE69828881D1 (de) 2005-03-10
ITRM970365A0 (cg-RX-API-DMAC7.html) 1997-06-18

Similar Documents

Publication Publication Date Title
DE69828881T2 (de) Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen
DE68905096T2 (de) Niacin und guar-mehl enthaltende zusammensetzung.
DE69901396T2 (de) Zusammensetzung enthaltend beta-hydroxy-beta-methylbutyratsäuere und mindestens ein aminosäure
DE3855113T2 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
JP4166951B2 (ja) 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
DE3688038T2 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
DE60132444T2 (de) Behandlung von reizkolon-syndrom oder -krankheit
DE60218193T2 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
US4221784A (en) Process and composition for treating disorders by administering lecithin
DE69201660T2 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
DE69806788T2 (de) Zusammensetzung zur unterdrückung von entzugssymptomen und alkoholabhängigkeit bei alkoholikern sowie prävention von alkoholmissbrauch bei gesunden personen
HEIMAN Cardiac toxicity with thioridazine-tricyclic antidepressant combination
DE69829290T2 (de) Verwendung von alkanoylcarnitinderivaten zur behandlung von hyperaktivität mit aufmerksamkeitsstörungen
DE68927519T2 (de) Behandlung von erhöhtem Blutdruck
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
DE60124516T2 (de) Kombination des lezithins mit ascorbinsäure
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
DE69511453T2 (de) Verwendung einer Kombination von Antineoplastonen zur Herstellung eines Arzneimittels zur Behandlung der Neurofibromatose
DE60306503T2 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE69127541T2 (de) Pharmazeutische zusammensetzung
KR20010021694A (ko) 스트레스 받는 자에 유용한 영양 조성물
DE2131679A1 (de) 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate
DE60203895T2 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
DE69214979T2 (de) Neue, dietätische Zubereitungen auf Basis von Phosphor-Lipidkomplexen sowie deren Verwendung bei Schlafstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee